Description: Oramed Pharmaceuticals, Inc., a pharmaceutical company, engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's products primarily comprise ORMD0801, an oral insulin capsule that is in Phase II clinical trials for the treatment of diabetes; and ORMD0901, an analog for GLP-1 gastrointestinal hormone that is in per-clinical trials. Its portfolio of product candidates is based on intellectual property that allows for the protection of proteins and polypeptides in the stomach, and for their absorption through the gastrointestinal wall. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Jerusalem, Israel.
Home Page: www.oramed.com
ORMP Technical Analysis
1185 Avenue of the Americas
New York,
NY
10036
United States
Phone:
844 967 2633
Officers
| Name | Title |
|---|---|
| Mr. Nadav Kidron Esq. | Pres, CEO & Exec. Chairman |
| Mr. David Silberman CPA | CFO & Treasurer |
| Mr. Joshua Hexter | Chief Operating & Bus. Officer |
| Dr. Miriam Kidron Ph.D. | Chief Scientific Officer & Director |
| Mr. Michael Rabinowitz | Chief Commercial Officer |
| Mr. Netanel Derovan | Chief Legal Officer & Company Sec. |
| Dr. Roy Eldor M.D., Ph.D. | Chief Medical Advisor & Member of the Scientific Advisory Board |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.0879 |
| Price-to-Sales TTM: | 117.9787 |
| IPO Date: | 2006-04-21 |
| Fiscal Year End: | August |
| Full Time Employees: | 0 |